Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.

Sader HS, Flamm RK, Dale GE, Rhomberg PR, Castanheira M

The Journal of antimicrobial chemotherapy1 Sept 2018Cited by 47 (Europe PMC)

PMID29901750DOI10.1093/jac/dky227PepBankPUB-29901750

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In XDR clinical isolates, murepavadin MIC50/90 was 0.12/0.25 mg/L.
In plain wordsIn lab tests, murepavadin MIC50/90 was 0.12/0.25 mg/L in XDR isolates.
Peptide
Murepavadin
Outcome
Not applicableMIC50 and MIC90
Study
Pseudomonas aeruginosan = 785
XDR clinical isolates
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Measurements
MIC50
0.12 mg/L
Not specified
MIC90
0.25 mg/L
Not specified
Source sentences
Summary
Murepavadin (MIC50/90, 0.12/0.25 mg/L) inhibited 96.7% of isolates at ≤0.5 mg/L and was 8-fold more active than colistin (MIC50/90, 1/2 mg/L).
1 context sentence(design, population, supporting numbers)
Summary · context
Susceptibility testing was performed by the reference broth microdilution method and EUCAST and CLSI interpretative criteria were applied.
Report a problemFND-2990175001
02LabIn vitro (cells)Activity measurement
In XDR clinical isolates, murepavadin inhibited 96.7% at ≤0.5 mg/L.
In plain wordsIn lab tests, murepavadin inhibited 96.7% of XDR isolates at ≤0.5 mg/L.
Peptide
Murepavadin
Outcome
Not applicableIsolate inhibition
Study
Pseudomonas aeruginosan = 785
XDR clinical isolates
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Measurements
Isolates inhibited
96.7%
≤0.5 mg/L
Source sentences
Summary
Murepavadin (MIC50/90, 0.12/0.25 mg/L) inhibited 96.7% of isolates at ≤0.5 mg/L and was 8-fold more active than colistin (MIC50/90, 1/2 mg/L).
1 context sentence(design, population, supporting numbers)
Summary · context
Susceptibility testing was performed by the reference broth microdilution method and EUCAST and CLSI interpretative criteria were applied.
Report a problemFND-2990175002
03LabIn vitro (cells)Activity measurement
In XDR clinical isolates, murepavadin was 8-fold more active than colistin.
In plain wordsIn lab tests, murepavadin was 8-fold more active than colistin in XDR isolates.
Peptide
Murepavadin
Outcome
IncreaseActivity versus colistin
Study
Pseudomonas aeruginosan = 785
XDR clinical isolates
Comparator
Colistin
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Source sentences
Summary
Murepavadin (MIC50/90, 0.12/0.25 mg/L) inhibited 96.7% of isolates at ≤0.5 mg/L and was 8-fold more active than colistin (MIC50/90, 1/2 mg/L).
1 context sentence(design, population, supporting numbers)
Summary · context
Susceptibility testing was performed by the reference broth microdilution method and EUCAST and CLSI interpretative criteria were applied.
Report a problemFND-2990175003
04LabIn vitro (cells)Activity measurement
In XDR clinical isolates, seven isolates (0.9%) had murepavadin MIC values above 4 mg/L.
In plain wordsIn lab tests, seven XDR isolates (0.9%) had murepavadin MIC values above 4 mg/L.
Peptide
Murepavadin
Outcome
Not applicableElevated MIC frequency
Study
Pseudomonas aeruginosan = 785
XDR clinical isolates
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Source sentences
Summary
Only seven isolates (0.9%) exhibited murepavadin MIC values >4 mg/L.
1 context sentence(design, population, supporting numbers)
Summary · context
Susceptibility testing was performed by the reference broth microdilution method and EUCAST and CLSI interpretative criteria were applied.
Report a problemFND-2990175004
05LabIn vitro (cells)Activity measurement
In tobramycin-non-susceptible XDR isolates, murepavadin MIC50/90 was 0.12/0.25 mg/L.
In plain wordsIn lab tests, murepavadin MIC50/90 was 0.12/0.25 mg/L in tobramycin-non-susceptible isolates.
Peptide
Murepavadin
Outcome
Not applicableActivity in tobramycin-non-susceptible isolates
Study
Pseudomonas aeruginosan = 412
Tobramycin-non-susceptible XDR isolates
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Measurements
MIC50
0.12 mg/L
Not specified
MIC90
0.25 mg/L
Not specified
Source sentences
Summary
Murepavadin remained active against isolates that were non-susceptible to colistin (n = 50; MIC50/90, 0.25/0.25 mg/L), ceftolozane/tazobactam (n = 231; MIC50/90, 0.12/0.25 mg/L) and/or tobramycin (n = 412; MIC50/90, 0.12/0.25 mg/L).
1 context sentence(design, population, supporting numbers)
Summary · context
Susceptibility testing was performed by the reference broth microdilution method and EUCAST and CLSI interpretative criteria were applied.
Report a problemFND-2990175007
06LabIn vitro (cells)Activity measurement
In ceftolozane/tazobactam-non-susceptible XDR isolates, murepavadin MIC50/90 was 0.12/0.25 mg/L.
In plain wordsIn lab tests, murepavadin MIC50/90 was 0.12/0.25 mg/L in ceftolozane/tazobactam-non-susceptible isolates.
Peptide
Murepavadin
Outcome
Not applicableActivity in ceftolozane/tazobactam-non-susceptible isolates
Study
Pseudomonas aeruginosan = 231
Ceftolozane/tazobactam-non-susceptible XDR isolates
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Measurements
MIC50
0.12 mg/L
Not specified
MIC90
0.25 mg/L
Not specified
Source sentences
Summary
Murepavadin remained active against isolates that were non-susceptible to colistin (n = 50; MIC50/90, 0.25/0.25 mg/L), ceftolozane/tazobactam (n = 231; MIC50/90, 0.12/0.25 mg/L) and/or tobramycin (n = 412; MIC50/90, 0.12/0.25 mg/L).
1 context sentence(design, population, supporting numbers)
Summary · context
Susceptibility testing was performed by the reference broth microdilution method and EUCAST and CLSI interpretative criteria were applied.
Report a problemFND-2990175006
07LabIn vitro (cells)Activity measurement
In colistin-non-susceptible XDR isolates, murepavadin MIC50/90 was 0.25/0.25 mg/L.
In plain wordsIn lab tests, murepavadin MIC50/90 was 0.25/0.25 mg/L in colistin-non-susceptible isolates.
Peptide
Murepavadin
Outcome
Not applicableActivity in colistin-non-susceptible isolates
Study
Pseudomonas aeruginosan = 50
Colistin-non-susceptible XDR isolates
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Measurements
MIC50
0.25 mg/L
Not specified
MIC90
0.25 mg/L
Not specified
Source sentences
Summary
Murepavadin remained active against isolates that were non-susceptible to colistin (n = 50; MIC50/90, 0.25/0.25 mg/L), ceftolozane/tazobactam (n = 231; MIC50/90, 0.12/0.25 mg/L) and/or tobramycin (n = 412; MIC50/90, 0.12/0.25 mg/L).
1 context sentence(design, population, supporting numbers)
Summary · context
Susceptibility testing was performed by the reference broth microdilution method and EUCAST and CLSI interpretative criteria were applied.
Report a problemFND-2990175005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.